JWS Consulting is a division of Johnson Winter & Slattery providing commercial consulting services.
Johnson Winter & Slattery is engaged by major businesses, investment funds and government agencies as legal counsel on important transactions and disputes throughout Australia and surrounding regions.
Our firm provides a diverse range of opportunities for talented, enthusiastic people to develop brilliant legal careers.
Our news and media coverage including major transaction announcements, practitioner appointments and team expansions.
We support a number of community initiatives and not for profit organisations across Australia through pro bono legal work and charitable donations.
We support a number of organisations through sponsorships.
James is a corporate lawyer specialising in mergers and acquisitions, private equity transactions and equity capital markets.
He advises clients from a variety of industries including private equity sponsors. He is an expert in all aspects of domestic and cross-border M&A deals including public (takeovers and schemes of arrangements) and privately negotiated transactions and ECM deals including cross-border listings on the ASX.
James is qualified in both Australia and the US, and has for many years advised US clients doing business in Australia and Australian clients doing business in the US.
James has been consistently recognised by his peers (Best Lawyers) for each of M&A (2010-2020), Private Equity (2013-2020), Corporate & Venture Capital Law (2020) and by his clients (Chambers) as a leading individual, again for each of Corporate/M&A, Private Equity (2011-2020) and Capital Markets (2016-2020). In Chambers he is described as “easily the best private equity lawyer we have dealt with, especially on cross-border deals”and is regarded as a "solutions-based lawyer who is very hands-on during a deal" and is lauded for producing "high-quality work quickly and with strong client interaction.”
Acting for Action Potential Venture Capital, a GSK fund, in Saluda Medical Series D financing round.
Acting for Exponent's portfolio company Big Bus in its acquisition of City Sightseeing.
Acting for Seven in various venture capital investments.
Acting for Carnegie in its investment in Renew Medical.
Acting in connection with various bolt-on acquisitions for its flight services business Aero-Care.
Acting in relation to the acquisition of Dun & Bradstreet’s Australian and New Zealand businesses.
Acting for the Australian Institute of Management in relation to CHAMP Venture’s investment into AIM’s training business.
Acting as Australian counsel for Arboretum Ventures in its participation in Cardiac Dimensions equity financing.
Acting in relation to its investment in swimwear company Seafolly.
Acting in relation to Archer’s secondary buy-out of mining services business LCR Group.
Acting in relation to its acquisition of Transaction Services Group.
Acting for CDC and its shareholders in their partial divestment to Quadrant Private Equity.
Acting for Gettheworldmoving in its sale to Virgin Pulse, a portfolio company of Insight.
Acting for Insight in its investment in email marketing business Campaign Monitor.
Acting in relation to Archer’s secondary buy-out of flight services business Aero-Care.
Acting in relation to its investment in sports apparel company 2XU.
Acting in relation to its acquisition of iconic Australian boot maker RM Williams.
Acting in relation to Archer’s acquisition of Lend Lease’s Primelife Aged Care business.
Acting in relation to Archer’s acquisition of the V8 Supercars business.
Acting for Virgin Active Australia and Virgin Group in the $1 billion divestment of 51% of the Virgin Active business to CVC.
Acting in its $3.6 billion acquisition of GoldCorp Inc.
Acting for EnGeneIC in its redomicile by schemes of arrangement to Bermuda.
Acting in its acquisition of all of the assets of Datasquirt Ltd (ASX:DSQ).
Acting on its $300 million merger with LEO Pharma.
Acting for Presidian (a specialist finance, warranty and motor insurance provider) and its shareholders in the sale of Presidian to McMillan Shakespeare Ltd (ASX:MMS).
Acting for Seven Group Holdings in its investment in iSeekplant.
Acting as Australian counsel in relation to Amobee’s acquisition of Adconion.
Acting in relation to Virgin’s sale of Virgin Money Australia to Bank of Queensland (ASX:BOQ).
Acting in relation to VET’s acquisition of Endeavour Learning and Real Institute.
Acting on the A$8 billion merger with Hutchison, and advised in relation to the acquisition of Crazy John’s.
Acting for VTI on its Australian IPO and ASX-listing.
Acting for AXP on its Australian IPO and ASX-listing and various fundraisings.
Acting for BSA in its placement and underwritten pro-rata entitlement offer.
Acting in relation to its PIPE by Standard Chartered Private Equity.
Acting for IPD in various fundraisings, including its underwritten pro-rata entitlement offer and placement.
Acting on its proposed IPO and ASX-listing.
Acting as Australian counsel in its financing of Spinifex.
Acting for OSP in relation to various fundraisings.
Acting in relation to SHC’s concurrent private placement of CDIs and (as Australian counsel) its IPO and Nasdaq-listing.
Acting on its proposed IPO and ASX-listing.
Acting in relation to VET’s IPO and ASX-listing.
Recognised as a key lawyer in corporate and M&A
Ranked as a leading lawyer in capital markets, private equity and corporate/mergers and acquisitions
Listed as a leading lawyer in mergers and acquisitions law
Listed as a leading lawyer in equity capital markets law
Listed as a leading lawyer in private equity law
Listed in the categories of corporate and venture capital law
One client describes James as "knowledgeable and responsive", adding that "he also understands US law and can help a US company publicly trade in Australia"
Recommended in corporate and mergers and acquisitions law
Recommended in capital markets
James Rozsa is ... particularly valued by clients as an adviser with "the rare quality of assessing risk rather than just identifying it and focusing on the stuff that poses genuine problems"
James Rozsa is highlighted for his "legal expertise and great professional advice," and also for his "great communication skills and management of investor expectations and concerns"
James Rozsa is described as a "solutions-based lawyer who is very hands-on during a deal," and is also lauded for producing "high-quality work quickly and with strong client interaction"
James Rozsa is praised by clients for his "tireless work on documentation" and for proving "good in both service and content"
James Rozsa is a "commercial problem solver who holds 'trusted adviser' status"
James Rozsa has "a great understanding of private equity deals and is always keen to provide innovative solutions”
James Rozsa is praised for being "very commercial, well-connected and solutions-oriented”
On 16 October 2017, the Broadcasting Legislation Amendment (Broadcasting Reform) Bill 2017 (Cth) was passed by Australia’s House of Representatives and granted Royal assent. Following the Royal...
There are a number of associated issues and uncertainties regarding a new exemption certificate for business acquisitions by foreign investors (Business EC).
In February 2017, the Australian Government released a consultation paper titled ‘Increasing Transparency of the Beneficial Ownership of Companies’ (Consultation Paper) to explore the potential to...